

CorMedix Inc.  
Form 8-K  
December 23, 2013

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 23, 2013

CORMEDIX INC.  
(Exact Name of Registrant as Specified in  
Charter)

Delaware 001-34673 20-5894890  
(State or Other  
Jurisdiction  
of  
Incorporation) (Commission  
File Number) (IRS Employer  
Identification  
No.)

745 Rt. 202-206,  
Suite 303,  
Bridgewater, NJ 08807  
(Address of  
Principal  
Executive (Zip  
Offices) Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed  
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

Item 8.01. Other Events.

On December 23, 2013, CorMedix Inc. issued a press release announcing that we received official minutes from our pre-IND meeting with the U.S. Food and Drug Administration concerning the development of Neutrolin® in the United States.

A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
----------------	-------------

<u>99.1</u>	Press release dated December 23, 2013.
-------------	--

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: December 23, 2013

By: /s/ Randy Milby  
Name: Randy Milby  
Title: Chief Executive Officer